(VCBeat) July. 30, 2021 -- Beijing Enze Kangtai Biotechnology Co., Ltd. ("Echo Biotech") announced the closing of a Series A financing of nearly 100 million yuan, led by Longmen Capital, with participation from TigerYeah Capital and Volcanics Venture. Instant Capital acted as the exclusive financial advisor. The proceeds from the financing will mainly be used for the construction of Echo Biotech's exosome therapy pilot plant, the development of pre-clinical series of products and the establishment of its exosome engineering technology platform.

Previously, Echo Biotech completed the angel round and Pre-Series A round in 2017 and 2018 respectively.

Echo Biotech was founded in 2017. The company is the first high-tech enterprise committed to exosome technology development and clinical transformation in China. Its business segments are mainly divided into: first, innovative drug research and development based on exosomes, mainly covering tumor immunity, rare diseases and neurological diseases; second, translational medicine research services based on exosomes, with cooperation with clinical experts to carry out scientific research. At present, the business has covered the major cities in China, and has established cooperation with more than 50 well-known first-class hospitals at grade 3 and scientific research institutions as well as many precision medicine enterprises.

Founded in 2017, Longman Capital focuses on investments in companies engaged in innovative medicine and life science technology in early and early-growth stages. The core team has a wealth of operation and investment experience in the pharmaceutical field. At present, it has initiated and established the third-phase fund, with a management scale of 2 billion yuan.

Founded in 2014, TigerYeah Capital is dedicated to build itself as a famous brand in the healthcare investment field and become a top-tier investment firm.  TigerYeah Capital focuses on early and growing equity investment in healthcare, especially in the field of medical devices, health food, CRO, and health services. By leveraging Tigermed solid platform and TigerYeah's abundant industrial resources,  TigerYeah Capital provides comprehensive post-investment services for entrepreneurs.